Niga-ichigoside F1

Research use only, not for human use.

Niga-ichigoside F1(NI) has anti-inflammatory, gastroprotective ,antinociceptive, and cytotoxic effects.

Niga-ichigoside F1(NI) has anti-inflammatory, gastroprotective ,antinociceptive, and cytotoxic effects.

Niga-ichigoside F1 (2.5, 5, 10, 20 μM; for 24 hours) inhibits lipid accumu-lation in free fatty acid (FFA)-treated HepG2 cells in a dose-dependent manner. Niga-ichigoside F1 has no effects on cell viability. Both nuclear and cytoplasmic Nrf2 expressions are lowered in Con, Niga-ichigoside F1 (20 μM), FFA (1 mM), and Niga-ichigoside F1 plus FFA treated Nrf2-silenced cells.

Niga-ichigoside F1 (40 mg/kg; oral gavage; for 12 weeks) alleviates hepatic steatosis, possibly by significantly interacting with high-fat diet (HFD) to regulate lipid metabolism genes (including Srebp1c, Acc1, Fasn, Scd1, Cpt1a and Fabp5) in four-week-old male C57BL/6J mice.

——

Others

Other Targets

——

——

——

95262-48-9

666.9

C36H58O11

>98% (HPLC)

——

——

——

(-20℃)

With Ice Pack

≥ 2 years